Stämm Biotech is building a desktop-sized bioreactor that 3D prints a dense network of microchannels to move cells through nutrients and oxygen, replacing tanks, stirrers and tubing. Its system is designed with a software component that configures channel designs and has been described as a “CDMO on the cloud.” The company says its approach can reduce the size of a biomanufacturing facility by two orders of magnitude and currently achieves outputs of about 30 liters, with a claimed potential to scale to roughly 5,000 liters. Commercialization is still early: Stämm is working with one European biopharma on biosimilars and has five potential partners in the pipeline, and it plans to move to pilot scale in 2022. Financially, Stämm closed a $17M Series A and has raised $20M in total (including prior seed and pre-seed rounds). The company is refining its microfluidic bioreactors and control tools, exploring business models, and plans to double headcount and expand internationally.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2022